✦ LIBER ✦

Pharmacokinetics of etanercept, a TNF antagonist, in patients with psoriasis treated in two double-blind phase 3 trials

✍ Scribed by Ivan Nestorov; Todd DeVries; Ralph Zitnik

Book ID: 116578968
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 56 KB
Volume: 50
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2003.10.515

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral ponesimod in patients with chronic

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

✍ Vaclavkova, Andrea; Chimenti, Sergio; Arenberger, Petr; Holló, Peter; Sator, Pau 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 517 KB

A randomized, multicenter, double-blind,

A randomized, multicenter, double-blind, placebo-controlled phase 2 trial of ISA247 in patients with chronic plaque psoriasis

✍ Robert Bissonnette; Kim Papp; Yves Poulin; Gilles Lauzon; Launa Aspeslet; Robert 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 167 KB

A 2-year phase 3 study of safety and eff

A 2-year phase 3 study of safety and efficacy of etanercept 50 mg twice weekly in patients with psoriasis: Results from the 3-month double-blind period

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Clinical efficacy and safety of etanerce

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: A randomized, double-blind trial

✍ Juergen Braun; Irene E. van der Horst-Bruinsma; Feng Huang; Ruben Burgos-Vargas; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

Secukinumab efficacy in patients with mo

Secukinumab efficacy in patients with moderate to severe plaque psoriasis and psoriatic arthritis: A phase II, double-blind, randomized trial

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Six-month results of a double-blind, pla

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

✍ J. Brandt; A. Khariouzov; J. Listing; H. Haibel; H. Sörensen; L. Grassnickel; M. 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract ## Objective There is increasing evidence that tumor necrosis factor α (TNFα) is centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate the efficacy of anti‐TNFα therapy with etanercept, a 75‐kd recepto